▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3528 by analyst upside · 2026-09-23
PBLS
Parabilis Medicines, Inc.
Healthcare · Market Cap $5B · P/E 0x
ANALYST PRICE TARGET
+9.4%
implied upside to consensus target
Current Price $38.17
Consensus Target $41.75
Bull Target $45.0
Bear Target $40.0
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
4
Hold
0
Sell
0
52-Week Low $24.51
52-Week High $42.49
YTD Return +0.0%
FUNDAMENTALS
Market Cap $5B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.88
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $24.51
52-Week High $42.49
Current Price $38.17
Bear Target $40.0
Bull Target $45.0
● Now $38.17 ● Target $41.75
TRADING DATA
Avg Volume 618K
YTD Return +0.0%
Analyst Count 4
Consensus Buy
Upside to Target +9.4%
Last Updated 2026-09-23

ANALYST SUMMARY

Parabilis Medicines, Inc. (PBLS) is currently trading at $38.17 with a Wall Street consensus price target of $41.75, implying potential upside of 9.4% over the next 12 months. 4 analysts currently cover PBLS, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $45.0, while the most cautious has a target of $40.0.

PBLS operates in the Healthcare sector with a market capitalisation of $5B. The stock is up 0.0% year-to-date and is currently trading near the upper end of its 52-week range of $24.51 – $42.49.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ACAD +28.3%
ACADIA Pharmaceuticals Inc.
$5B · P/E 11.8x · Buy
INDV +35.4%
Indivior Pharmaceuticals, Inc.
$4B · P/E 13.0x · Buy
GRFS +46.0%
Grifols, S.A.
$5B · P/E 9.8x · Buy
CON +17.5%
Concentra Group Holdings Parent, Inc.
$4B · P/E 22.5x · Buy
LIVN +13.5%
LivaNova PLC
$4B · P/E 23.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for PBLS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Guggenheim ● Initiated
Buy 2026-07-06 62% win rate (8 calls)
Leerink Partners ● Initiated
Outperform 2026-07-06 29% win rate (7 calls)
B of A Securities ● Initiated
Buy 2026-07-06 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
66
out of 100
Coverage depth
12/30
Consensus clarity
27/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →